DSGN - Company ID 0001807120
The table below shows Design Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | - | - | - | $226.00K |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $59.13M | $44.35M | $57.06M | $48.61M | $24.78M | $6.06M |
| SG&A |
Design Therapeutics, Inc. reported annual revenue of $0.00 for fiscal year 2025. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $20.34M |
| $18.03M |
| $21.13M |
| $18.98M |
| $11.05M |
| $2.50M |
| Operating income | -$79.47M | -$62.38M | -$78.19M | -$67.59M | -$35.83M | -$8.33M |
| Income tax | $0.00 | $0.00 | - | - | - | - |
| Net income | -$69.79M | -$49.59M | -$66.86M | -$63.31M | -$35.53M | -$8.28M |
| EPS (diluted) | -$1.22 | -$0.88 | -$1.19 | -$1.14 | -$0.77 | - |